Amylyx Pharmaceuticals (AMLX)
(Real Time Quote from BATS)
$1.90 USD
+0.03 (1.60%)
Updated May 15, 2024 01:28 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/8/24 |
---|---|
Current Quarter | -0.38 |
EPS Last Quarter | -0.46 |
Last EPS Surprise | -291.67% |
ABR | 2.71 |
Earnings ESP
|
36.84% |
---|---|
Current Year | -1.79 |
Next Year | -1.17 |
EPS (TTM) | 0.22 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 18.83M | NA | 107.45M | NA |
# of Estimates | 2 | NA | 2 | NA |
High Estimate | 20.40M | NA | 109.00M | NA |
Low Estimate | 17.25M | NA | 105.89M | NA |
Year ago Sales | 98.22M | 102.69M | 380.79M | 107.45M |
Year over Year Growth Est. | -80.83% | NA | -71.78% | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.38 | -0.38 | -1.79 | -1.17 |
# of Estimates | 2 | 2 | 3 | 3 |
Most Recent Consensus | -0.24 | NA | -2.30 | -1.05 |
High Estimate | -0.24 | -0.19 | -1.28 | -0.90 |
Low Estimate | -0.52 | -0.57 | -2.30 | -1.56 |
Year ago EPS | 0.31 | 0.30 | 0.70 | -1.79 |
Year over Year Growth Est. | -222.58% | -226.67% | -355.71% | 34.45% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 1 |
Up Last 30 Days | 0 | 0 | 0 | 1 |
Up Last 60 Days | 0 | 0 | 1 | 2 |
Down Last 7 Days | 1 | 0 | 2 | 1 |
Down Last 30 Days | 1 | 0 | 2 | 1 |
Down Last 60 Days | 1 | 0 | 2 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.38 | -0.38 | -1.79 | -1.17 |
7 Days Ago | -0.38 | -0.38 | -1.01 | -1.10 |
30 Days Ago | -0.38 | -0.38 | -1.01 | -1.10 |
60 Days Ago | -0.25 | -0.23 | -0.83 | -0.77 |
90 Days Ago | 0.21 | 0.23 | 1.55 | 1.44 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.24 | -0.38 | -2.04 | -0.98 |
Zacks Consensus Estimate | -0.38 | -0.38 | -1.79 | -1.17 |
Earnings ESP | 36.84% | 0.00% | -14.18% | 16.67% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.46 | 0.07 | 0.30 | 0.31 | NA |
Estimate | 0.24 | 0.20 | 0.42 | 0.01 | NA |
Difference | -0.70 | -0.13 | -0.12 | 0.30 | -0.16 |
Surprise | -291.67% | -65.00% | -28.57% | 3,000.00% | 653.69% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more